TERF1 and cancer: Then, monocytes derived exosomal miR‐155 target telomeric repeat binding factor 1 (TERF1), a component of the shelterin complex, in NBL cells and induce the acquisition of cisplatin resistance.[92] Additionally, exosome‐transmitted miR‐155 facilitates the cisplatin resistance in OSCC cells.[93] Shen et al. demonstrate that breast cancer cells could release various EV miRNAs after chemotherapy, such as miR‐203a‐3p, miR‐195‐5p, and miR‐9‐5p, which concurrently targets the transcription factor One Cut Homeobox 2 (ONECUT2), inducing cancer stem cell‐like features and chemotherapy resistance.[94]